MENU

Virtus Health Ltd expands to the UK

Virtus Health Ltd (ASX: VRT) is Australia’s largest assisted reproductive provider.

Earlier today, Virtus announced that it will be expanding into the UK.

The IVF company has exchanged contracts for the acquisition of 90% of the ordinary share capital of Complete Fertility Limited based at the Princess Anne Hospital in Southampton for a ‘cash free debt free’ consideration of approximately £5 million ($8.8 million) at a multiple of approximately seven times normalised FY17 earnings before interest, tax, depreciation and amortisation (EBITDA).

The ‘cash free debt free’ consideration is funded from existing cash and debt resources.

The transaction also includes an agreement for Complete Fertility to acquire the business and assets relating to fertility services by the University Hospital Southampton NHS Foundation Trust.

Virtus Health CEO, Sue Channon, said “The UK is a target market for Virtus and this acquisition adds to Virtus’ international growth strategy reaffirming our vision for diversification and expansion of the Virtus model in carefully selected international markets.”

“CFL is highly regarded in the UK providing fertility treatments to NHS and private patients and its clinicians are at the forefront of research and development in the area of assisted reproductive services”.

Virtus said that CFL performed 420 fresh IVF cycles in the year ended 31 March 2017 and has achieved further growth during the nine months to December 2017.

The centre is located on the south coast of the Britain and has around 50% of the regional market share. Virtus believes it offers significant opportunity for future growth.

Foolish takeaway

Virtus expect that this acquisition will be earnings per share (EPS) accretive in FY19. This seems like a clever acquisition and will give Virtus a foothold into the large UK market. It’s currently trading at 14x FY18’s estimated earnings with a grossed-up dividend yield of 6.77%.

I think Virtus offers investors an attractive long-term growth opportunity at the current price and is worth further research.

I also believe that these top stocks also offer very good long-term opportunities to investors.

Top 3 ASX Blue Chips To Buy In 2018

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.